Home » Regeneron Announces Settlement With Genentech for U.S. Sales of Eylea
Regeneron Announces Settlement With Genentech for U.S. Sales of Eylea
Regeneron Pharmaceuticals announced that it has entered into a non-exclusive license and partial settlement agreement with Genentech relating to U.S. sales of Eylea (aflibercept) injection.
MarketWatch
MarketWatch
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May